Sotyktu (deucravacitinib) — Point32Health

Initial criteria

• Documented diagnosis of plaque psoriasis
• Patient age ≥ 6 years
• Prescribed by or in consultation with a dermatologist
• Documentation of one of the following: (a) Trial and failure of at least two of the listed medications from each of the following therapeutic categories (only one medication is required if only one is available for a listed therapeutic category): Interleukin Antagonists (Bimzelx, Skyrizi, Taltz, Tremfya, Yesintek); Phosphodiesterase 4 inhibitors (Otezla); Tumor Necrosis Factors (Cimzia, Enbrel, Humira); OR (b) Contraindication to all the following medications: Bimzelx, Skyrizi, Taltz, Tremfya, Yesintek, Otezla, Cimzia, Enbrel, Humira